Cetuximab, fluorouracil ( 5-FU) and cisplatin alone or with docetaxel in recurrent and/or metastatic head and neck cancer.

Trial Profile

Cetuximab, fluorouracil ( 5-FU) and cisplatin alone or with docetaxel in recurrent and/or metastatic head and neck cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2015

At a glance

  • Drugs Docetaxel (Primary) ; Cetuximab; Cisplatin; Fluorouracil
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Feb 2015 Status changed from recruiting to completed as reported by European Clinical Trial database.
    • 03 Jun 2014 Primary endpoint has not been met. (Progression-free survival)
    • 03 Jun 2014 First analysis findings presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top